Close Menu

Xavier Reveles

Jun 28, 2017

Bioaffinity Technologies announced the addition of Xavier Reveles as director of operations. He will manage the commercialization of Bioaffinity's diagnostic and therapeutic products. Reveles has 25 years of experience as a clinical geneticist and was laboratory director for Oncopath Laboratory-START Cancer Center. 

More Like This

Apr 24, 2019

Andrew Last

Bio-Rad has appointed Andrew Last as Executive Vice President and Chief Operating Officer, responsible for all operating functions of the company on a global basis. Last was most recently CCO at Berkeley Lights and prior to that he served as COO at Intrexon Corporation. He was EVP and COO at Affymetrix between 2010 and 2016, and has also previously held senior positions at BD, Applied Biosystems, Incyte Genomics, and Monsanto.

Apr 23, 2019

Bahija Jallal

Guardant Health has appointed Bahija Jallal to its Board of Directors, effective April 17. Jallal has served as the CEO of Immunocore Limited, a T cell receptor biotechnology company, since January 2019. Prior to that she served as executive vice president of AstraZeneca PLC and was president of MedImmune, a subsidiary of AstraZeneca after holding various other research and development positions at the company.

Jallal is a member of the of the Board of Trustees of Johns Hopkins University and of UMB Health Sciences Research Park Corporation, and served as past president of the Association for Women in Science.

Apr 23, 2019

Joseph Frendo

Caris Life Sciences announced Joseph Frendo has joined the company as chief operations officer. He was senior vice president of PBM Operations at CVS health. Prior to that, he held various management positions at Medco Health Solutions. In his role at Caris, Frendo will direct technical and clinical staff operations and guide strategies to advance quality and optimize efficiences across the firm, Caris said. 

 

Apr 18, 2019

Ori Karev

Ori Karev has joined Precipio as chief strategy officer. Karev was formerly CEO of UnitedHealthcare Global, the international division of United Healthcare. He also previously worked for Ernst & Young. An attorney by training, Karev has more than 30 years of experience in the healthcare, insurance, and mobility industries, Precipio said.

Apr 17, 2019

Carsten Ullrich

Centogene has appointed Carsten Ullrich its director of artificial intelligence. He will direct the firm's use of AI to enhance diagnostic effectiveness and quality, and to discover new insights, accelerate biomarker development, and drive solutions for drug firms. Ullrich was most recently associate head of a research lab and senior researcher at the German Research Center for Artifidal Intelligence. 

Apr 15, 2019

Amy Winslow

Amy Winslow was named president of BioPorto Diagnostics, the US subsidiary of BioPorto. She will be responsible for building and leading the US operation as it prepares to launch the NGAL Test for identifying acute kidney injury before permanent damage occurs. The company expects the US Food and Drug Administration to clear the test later this year. Winslow was most recently president and CEO of Magellan Diagnostics, an independent business unit of Meridian Bioscience. Prior to that, she was vice president of marketing for Athena Diagnostics. 

Apr 12, 2019

Axel Sjöblad

SenzaGen has appointed Axel Sjöblad its CEO, effective June 17. He replaces Anki Malmborg Hager who was CEO for five years and is becoming a member of the firm's board. Sjöblad was most recently CEO of BioGaia. Before that, he was president of sales and service North Europe and CEO of Getinge Sverige. He also was regional vice president Northern European markets at Gambro. Based in Sweden SenzaGen develops in vitro assays for immunotoxicity testing.

Apr 10, 2019

Gary Winer

German speciality diagnostics company Orgentec Diagnostika's board has appointed Gary Winer the firm's president and CEO, effective immediately. Winer has held senior leadership positions with companies including AbbVie, Abbott Laboratories, and Pfizer. At Abbott, he managed the firm's diagnostics business in the US, Canada, and Latin America before he was promoted to lead Abbott Japan. 

Apr 10, 2019

Andrew Connerty

Andrew Connerty has been appointed vice president of quality assurance and regulatory affairs for First Light Diagnostics. He has more than 25 years of quality systems management expertise at a strategic and tactical level and has worked at Johnson & Johnson, Confluent Surgical, SeraCare Life Sciences, RainDance Technologies, and Bio-Rad Laboratories. 

Apr 05, 2019

Karen Koski

Karen Koski has been appointed the chief business officer for Specific Diagnostics, effective April 8. She was previously with Oxford Immunotec as vice president of strategy and investor relations. Prior to that, she was a director and senior equity analyst at BTIG. 

Apr 03, 2019

Ilan Daskal

Bio-Rad Laboratories has appointed Ilan Daskal as executive vice president and CFO. Daskal previously served as CFO of Lumileds, a lighting manufacturer formed in 1999 as a joint venture between Philips Lighting and Agilent Technologies. He will replace Christine Tsingos, who is retiring.

Apr 03, 2019

Parag Mallick

Parag Mallick has been appointed to the scientific board of Oncimmune Holdings. He is an associaate professor of radiology at Stanford University and a member of the Canary Center for Cancer Early Detection. His research focuses on approaches using big data, mathematical modeling, and machine learning to discover cancer biomarkers for personalized and predictive medicine. 

Apr 02, 2019

Michael Deppe

Quest Diagnostics said in a document filed with the US Securities and Exchange Commission that Michael Deppe was elected vice president, corporate controller and chief accounting officer and the company's principal accounting officer. Deppe joined Quest in 1998 and has served in various account and finance leadership positions, including president of finance-enterprise operation and IT from August 2015 to March 2019. Before joining the company, he started his career at PricewaterhouseCoopers. 

Apr 02, 2019

Flemming Ornskov

Flemming Ornskov was appointed to Centogene's supervisory board and elected its non-executive chairman, effective April 1. He most recently was CEO of Shire. Prior to that, he held senior positions at several pharmaceutical firms, such as Bayer, Novartis, and Merck & Co. As a non-executive chairman, Ornskov will oversee Centogene's strategy development, US expansion, and strategic M&A. 

Apr 02, 2019

Steve Fletcher, Tim Dwyer, Joseph Fitchett, Stephen Crossland, Andrew Wheeler

Mologic has announced the opening of a US subsidiary and key appointments for its US and United Kingdom sites.

The firm announced Steve Fletcher as president and chief commercial officer of Mologic Inc. and head of the firm's US headquarters located just outside of Boston, Massachusetts.

Fletcher has more than 25 years of experience in leading marketing, product, and business operations for global healthcare companies, including 3M, Thermo Fisher Scientific, and GC America.

Mologic also appointed Tim Dwyer as its chief technology officer. Dwyer is a fellow of the Royal Society of Biology with more than 19 years of experience in the design and development of diagnostic devices on multiple immunoassay platform technologies.

The firm appointed Joseph Fitchett as its chief medical officer and head of global health to support the expansion of its UK facilities. In his previous role as a program officer at the Bill & Melinda Gates Foundation, Fitchett advanced the foundation’s bilateral partnerships with European Union donors, including advancing the manufacturing capacity of yellow fever vaccine and infectious disease surveillance and control, at the Institut Pasteur in Dakar.

In the US, Mologic also appointed Stephen Crossland as vice president of sales and business development and Andrew Wheeler as R&D manager.